伴血脂异常2型糖尿病患者亚甲基四氢叶酸还原酶基因多态性与血浆同型半胱氨酸水平的相关性

doi:10.24920/003532

Abstract

Objective To investigate the association between total homocysteine (tHcy) level in plasma and methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C genetic polymorphisms in a Chinese Han nationality population with type 2 diabetes mellitus (T2DM) accompanied by dyslipidemia.
Methods This case-control study enrolled T2DM patients with dyslipidemia and without dyslipidemia respectively. Sanger dideoxy-mediated chain-termination method was used to detect the gene polymorphisms of MTHFR C677T and A1298C. Plasma tHcy and lipid levels were measured as well. The genotype frequency and allele frequency between the dyslipidemia and non-dyslipidemia groups were compared by using Chi-square test. Plasma tHcy level of T2DM patients who carried the different genotypes was compared by Student’s t test.
Results Finally, 82 T2DM patients with dyslipidemia and 94 ones without dyslipidemia were included in this study. There was a significant correlation between tHcy level and MTHFR C677T gene polymorphism in T2DM patients (t=2.27, P=0.02). Moreover, the plasma tHcy level in the dyslipidemia patients who carried MTHFR 677 TT genotype was significantly higher than that in those with CT+CC genotype (13.62±6.97 vs. 10.95±3.62 μmol/L, t=2.20, P=0.03); while for patients without dyslipidemia, comparison of the tHcy level between those who carried the above two alleles showed no significantly difference (13.34±6.03 vs. 12.04±5.09 μmol/L, t=1.08, P=0.29).
Conclusion MTHFR 677TT genotype might associate with higher tHcy level in T2DM patients with dyslipidemia.

Key words: type 2 diabetes mellitus, methylenetetrahydrofolate reductase, polymorphism, homocysteine, hyperlipidemia

Yin Ying, Li Rui, Li Xiaoli, Wu Kunrong, Li Ling, Xu Yuedong, Liao Lin, Yang Rui, Li Yan. Association Between Homocysteine Level and Methylenetetrahydrofolate Reductase Gene Polymorphisms in Type 2 Diabetes Accompanied by Dyslipidemia[J].Chinese Medical Sciences Journal, 2020, 35(1): 85-91.

Figures/Tables 4

Table 1

Figure 1.

Table 2

Table 3

References 31.

1.	Mottillo S, Filion KB, Genest J , et al. The metabolic syndrome and cardiovascular risk. A systematic review and meta-analysis. J Am Coll Cardiol 2010; 56(14):1113-32. doi: 10.1016/j.jacc.2010.05.034.
2.	Fox CS, Coady S, Sorlie PD , et al. Trends in cardiovascular complications of diabetes. JAMA 2004; 292(20):2495-9. doi: 10.1001/jama.292.20.2495.
3.	Outinen PA, Sood SK, Liaw PC , et al. Characterization of the stress-inducing effects of homocysteine. Biochem J 1998; 332(1):213-21.
4.	Pollex RL, Mamakeesick M, Zinman B , et al. Methylenetetrahydrofolate reductase polymorphism 677C>T is associated with peripheral arterial disease in type 2 diabetes. Cardiovasc Diabetol 2005; 4(1):17. doi: 10.1186/1475-2840-4-17.
5.	Hoogeveen EK, Kostense PJ, Beks PJ , et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 1998; 18(1):133-8. doi: 10.1161/01.ATV.18.1.133.
6.	Hackam DG . Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 2003; 290(7):932-40. doi: 10.1001/jama.290.7.932.
7.	Klerk M, Verhoef P, Clarke R , et al. MTHFR 677C T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002; 288(16):2023-31. doi: 10.1001/jama.288.16.2023.
8.	Audelin MC, Genest J . Homocysteine and cardiovascular disease in diabetes mellitus. Atherosclerosis 2001; 159:497-511. doi: 10.1016/s0021-9150(01)00531-7.
9.	Harmon DL, Woodside JV, Yarnell JW , et al. The common ‘thermolabile’ variant of methylenetetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. QJM 1996; 89(8):571-7. doi: 10.1093/qjmed/89.8.571.
10.	van der Put NM, Gabreëls F, Stevens EM , et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998; 62(5):1044-51. doi: 10.1086/301825.
11.	Frosst P, Blom HJ, Milos R , et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10(1):111-3. doi: 10.1038/ng0595-111.
12.	Arnadottir M, Hultberg B, Nilsson-Ehle P , et al. The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest 1996; 56(1):41-6. doi: 10.3109/00365519609088586.
13.	Rozycka A, Jagodzinski PP, Kozubski W , et al. Homocycsteine level and mechanisms of injury in Parkinson’s disease as related to MTHFR, MTR, THFD1 genes polymorphisms and L-Dopa treatment. Curr Genomics 2013; 14(8):534-42. doi: 10.2174/1389202914666131210210559.
14.	Krumdieck CL, Prince CW . Mechanisms of homocysteine toxicityon connective tissues: implications for the morbidity of aging. J Nutr 2000; 130(2S Suppl):365S-8S. doi: 10.1093/jn/130.2.365S.
15.	Haynes WG . Hyperhomocysteinaemia, vascular function and athersclerosis: effects of vitamins. Cadiovasc Drugs Ther 2002; 16(5):391-9.
16.	Glueck CJ, Shaw P, Lang JE , et al. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 1995; 75(2):132-6. doi: 10.1016/s0002-9149(00)80061-2.
17.	Goyette P, Sumner JS, Milos R , et al. Human methylenetetrahydrofolate reductase: isolation of cDNA mapping and mutation identification. Nat Genet 1994; 7(4):551.
18.	Doshi SN, Goodfellow J, Lewis MJ , et al. Homocysteine and endothelial function. Cardiovasc Res 1999; 42(3):578-82. doi: 10.1016/s0008-6363(99)00029-2.
19.	Hanson NQ, Aras O, Yang F . C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease. Clin Chem 2001; 47(4):661-6.
20.	Spiridonova MG, Stepanov VA, Pyzyrev VP . Relationship between polymorphism C677T of the methylenetetrahydrofolate reductase gene with clinical symptoms of coronary atherosclerosis. Genetika 2000; 36(9):1269-73.
21.	Liang R, Zhou Y, Xie J , et al. Association of C677T gene polymorphisms of methylenetetrahydrofolate reductase and plasma homocysteine level with hyperlipidemia. Nan Fang Yi Ke Da Xue Xue Bao 2014; 34(8):1195-8. doi: 10.3969/j.issn.1673-4254.2014.08.25.
22.	Mao Y, Fan YH, Bai J , et al. Polymorphism of methylenetetrahydrofolate reductase and association with diseases. Int J Genetics 1998; 15(5):38-40.
23.	Cortese C . MTHFR gene polymorphism, homocysteine and cardiovascular disease. Public Health Nutr 2001; 4(2b):493-7. doi: 10.1079/PHN2001159.
24.	Errera FI, Silva ME, Yeh E , et al. Effect of polymorphisms of the MTHFR and APOE genes on susceptibility to diabetes and severity of diabetic retinopathy in Brazilian patients. Braz J Med Biol Res 2006; 39(7):883-8. doi: 10.1590/S0100-879X2006000700005.
25.	Benrahma H, Abidi O, Melouk L , et al. Association of the C677T polymorphism in the human methylenetetrahydrofolate reductase (MTHFR) gene with the genetic predisposition for type 2 diabetes mellitus in a Moroccan population. Genet Test Mol Biomarkers 2012; 16(5):383-7. doi: 10.1089/gtmb.2011.0179.
26.	Sun J, Xu Y, Zhu Y . Genetic polymorphism of methylenetetrahydrofolate reductase as a risk factor for diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Res Clin Pract 2004; 64(3):185-90. doi: 10.1016/j.diabres.2003.10.022.
27.	Doupis J, Eleftheriadou I, Kokkinos A , et al. Acute hyperhomocysteinemia impairs endothelium function in subjects with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2010; 118(7):453-8. doi: 10.1055/s-0030-1248290.
28.	Aso Y, Yoshida N, Okumura K , et al. Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia. Clin Chim Acta 2004; 348(1-2):139-45. doi: 10.1016/j.cccn.2004.05.006.
29.	Araki A, Sako Y, Ito H . Plasma homocysteine concentrations in Japanese patients with non-insulin-dependent diabetes mellitus: effect of parenteral methylcobalamin treatment. Atherosclerosis 1993; 103(2):149-57. doi: 10.1016/0021-9150(93)90258-v.
30.	Fekih-Mrissa N, Mrad M, Ibrahim H , et al. Methylenetetrahydrofolate reductase (MTHFR) (C677T and A1298C) polymorphisms and vascular complications in patients with type 2 diabetes. Can J Diabetes 2017; 41(4):366-71. doi: 10.1016/j.jcjd.2016.11.007.
31.	Sun JZ, Xu Y, Lu H . Polymorphism of the methylenetetrahydrofolate reductase gene association with homocysteine and ischemic stroke in type 2 diabetes. Neurol India 2009; 57(5):589-93. doi: 10.4103/0028-3886.57808.

Groups	n	Age (rs)	Height (m)	Weight (kg)	BMI (kg/m²)	Disease duration(rs)	HbA1c (%)	TC (mmol/L)	TG (mmol/L)	LDL-C (mmol/L)	HDL-C (mmol/L)	tHcy (μmol/L)
T2DM without dyslipidemia	94	59.6± 10.34	1.68± 0.08	69.38± 10.58	24.62± 3.27	11.41± 8.21	8.37± 1.83	4.05± 0.64	0.97± 0.33	2.23± 0.56	1.34± 0.24	12.57± 5.50
T2DM with dyslipidemia	82	59.72± 9.94	1.68± 0.07	72.99± 11.10	25.89± 3.21	9.40± 7.60	8.00± 1.57	4.62± 1.31	1.67± 0.95	2.71± 0.92	1.14± 0.35	12.22± 5.60
t value		-0.07	0.31	-2.21	-2.58	1.67	1.43	-3.78	-6.70	-4.27	4.51	0.42
P value		0.94	0.76	0.03	0.01	1.00	0.15	<0.05	<0.05	<0.05	<0.05	0.68

Groups	n	MTHFR C677T genotype			MTHFR C677T allele		MTHFR A1298C genotype		MTHFR A1298C allele
Groups	n	CC	CT	TT	C	T	AA	AC+CC	A	C
T2DM without dyslipidemia	94	12(12.77)	43(45.74)	39(41.49)	67(35.64)	121(64.36)	65(69.15)	29(30.85)	159(84.57)	29(15.43)
T2DM with dyslipidemia	82	6(7.32)	37(45.12)	39(47.56)	49(29.88)	115(70.12)	62(75.61)	20(24.39)	143(87.20)	21(12.80)
χ²		1.46	0.01	0.65		1.32		0.91		0.49
P		0.32	1.00	0.45		0.26		0.40		0.54

Groups	n	MTHFR C677T		t	P	MTHFR A1298C		t	P
Groups	n	TT	CT+CC	t	P	AA	AC+CC	t	P
All the subjects	176	13.48±6.48	11.56±4.52	2.27	0.02	12.47±5.80	12.24±4.86	0.24	0.81
T2DM with dyslipidemia	82	13.62±6.97	10.95±3.62	2.20	0.03	12.34±6.1	11.86±3.51	0.33	0.74
T2DM without dyslipidemia	94	13.34±6.03	12.04±5.09	1.08	0.29	12.60±5.48	12.50±5.65	0.06	0.95

[1]	Kunrong Wu, Shufang Zhang, Ziwan Guan, Xiaoli Li, Rui Li, Ying Yin, Yan Li. Methylenetetrahydrofolate Reductase Gene Polymorphism C677T is Associated with Increased Risk of Coronary Heart Disease in Chinese Type 2 Diabetic Patients [J]. Chinese Medical Sciences Journal, 2021, 36(2): 103-109.
[2]	Shen Chang, Zhao Meng, Li Yunyun, Liu Ningpu. Methylenetrahydrofolate Reductase Gene C677T Polymorphism and Diabetic Retinopathy: a Meta-Analysis [J]. Chinese Medical Sciences Journal, 2020, 35(1): 71-84.
[3]	Tang Hui,Zhu Xiaowei,Wu Longfei,Mo Xingbo,Deng Feiyan,Lei Shufeng. Integrative Analysis Confirmed the Association between Osteoprotegerin and Osteoporosis [J]. Chinese Medical Sciences Journal, 2019, 34(2): 147-156.
[4]	Li Jian-ping, Fu Yong-ping, Chang Wen-xiu, Yi Chang-rong, Liu Li-hua, Xing Hai-yan. Functional Variant of C-689T in the Peroxisome Proliferator-Activated Receptor-γ2 Promoter is Associated with Coronary Heart Disease in Chinese Nondiabetic Han People [J]. Chinese Medical Sciences Journal, 2017, 32(3): 177-184.
[5]	Chen Zhiye, Zang Xiujuan, Liu Mengqi, Liu Mengyu, Li Jinfeng, Gu Zhaoyan, Ma Lin. Abnormal Alterations of Cortical Thickness in 16 Patients with Type 2 Diabetes Mellitus: A Pilot MRI Study^△ [J]. Chinese Medical Sciences Journal, 2017, 32(2): 75-82.
[6]	Lan-wen Han, Dou-dou Ma, Xiao-jie Xu, Fang Lü, Yi Liu, Wei-bo Xia, Yan Jiang, Ou Wang, Xiao-ping Xing, Mei Li. Association Between Geranylgeranyl Pyrophosphate Synthase Gene Polymorphisms and Bone Phenotypes and Response to Alendronate Treatment in Chinese Osteoporotic Women [J]. Chinese Medical Sciences Journal, 2016, 31(1): 8-16.
[7]	Ying Fan, Shan-xiao Zhang, Meng Ren, Li-feng Hong, Xiao-ni Yan. Impact of 1, 25-(OH)₂D₃ on Left Ventricular Hypertrophy in Type 2 Diabetic Rats [J]. Chinese Medical Sciences Journal, 2015, 30(2): 114-120.
[8]	Lei Qiu, Jing Liu, Qi-ming Hei. Association between Two Polymorphisms of Follicle Stimulating Hormone Receptor Gene and Susceptibility to Polycystic Ovary Syndrome: a Meta-analysis [J]. Chinese Medical Sciences Journal, 2015, 30(1): 44-50.
[9]	Chao-xian Zhang, Yong-mei Qin, Li-ke Guo. Correlations Between Polymorphisms of Extracellular Superoxide Dismutase, Aldehyde Dehydrogenase-2 Genes, as Well as Drinking Behavior and Pancreatic Cancer [J]. Chinese Medical Sciences Journal, 2014, 29(3): 162-166.
[10]	Yu Deng,Xiu-fen Yang,Hong Gu,Apiradee Lim,Munkhtulga Ulziibat,Torkel Snellingen,Jun Xu,Kai Ma,Ning-pu Liu. Association of C(-106)T Polymorphism in Aldose Reductase Gene with Diabetic Retinopathy in Chinese Patients with Type 2 Diabetes Mellitus [J]. Chinese Medical Sciences Journal, 2014, 29(1): 1-6.
[11]	Yi-jun Zhou*,Ai Li, Yu-ling Song, Hui Zhou, Yan Li, Yin-si Tang. Role of Sclerostin in the Bone Loss of Postmenopausal Chinese Women with Type 2 Diabetes [J]. Chinese Medical Sciences Journal, 2013, 28(3): 135-139.
[12]	Yu-jing Sun, Ming-wu Fang, Wen-quan Niu, Guang-ping Li, Jing-liang Liu, Shou-quan Ding, Ying Xu, Guo-shu Yu, Jian-qun Dong, Yun-jun Pan,Wei-ya Dong, Tian Wang, Jing-wen Cao, Xiao-bo Li, Zhong-xiang Wang, Guang-xue Yu, Hui-cheng Sun, Zhong-hou Jia, Jun Liu, Xiao-ming Wang, Qin Si, Qi-xia Wu, Wen-yu Zhou, Tong-chun Zhu and Chang-chun Qiu. Endothelial nitric oxide synthase gene polymorphisms associated with susceptibility to high altitude pulmonary edema in Chinese railway construction workers at Qinghai-Tibet over 4 500 meters above sea Level [J]. Chinese Medical Sciences Journal, 2010, 25(4): 215-222.

Early edition

Current issue

Archive

Specialties & Topics

Author center

Reviewer center

Association Between Homocysteine Level and Methylenetetrahydrofolate Reductase Gene Polymorphisms in Type 2 Diabetes Accompanied by Dyslipidemia

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 31.

Related Articles 12

Metrics

Recommended 6